Relationship between toxoplasmosis and schizophrenia: A review

Advances in Clinical and Experimental Medicine

Volumn 26, Issue 6, 2017, Pages 1033-1038

  Fuglewicz, Aleksander J ^a   Piotrowski, Patryk ^a   Stodolak, Anna ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Neuropsychiatric symptoms; Schizophrenia; Toxoplasma gondii

Indexed keywords

NEUROLEPTIC AGENT; NEUROTRANSMITTER; ANTIPARASITIC AGENT;

BRAIN CELL; BRAIN GROWTH; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; NERVOUS SYSTEM INFLAMMATION; PREGNANCY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; TOXOPLASMA GONDII; TOXOPLASMOSIS; CEREBRAL TOXOPLASMOSIS; ODDS RATIO; PARASITOLOGY; PREVALENCE; PSYCHOLOGY; RISK ASSESSMENT; RISK FACTOR;

ANTIPARASITIC AGENTS; ANTIPSYCHOTIC AGENTS; HUMANS; ODDS RATIO; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TOXOPLASMOSIS, CEREBRAL;

EID: 85031035460     PISSN: 18995276     EISSN: 24512680     Source Type: Journal    
DOI: 10.17219/acem/61435     Document Type: Review

References (40)

1. Flegr J, Prandota J, Sovickova M, Israili ZF. Toxoplasmosis -A global threat: Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. PLoS ONE. 2014; 9: e90203.
2. Jones JL, Parise ME, Fiore AE. Neglected parasitic infections in the United States: Toxoplasmosis. Am J Trop Med Hyg. 2014; 90: 794-799.
3. McConkey GA, Martin HL, Bristow GC, Webster JP. Toxoplasma gondii infection -location, location, location? J Exp Biol. 2013; 216: 113-119.
4. Henriquez SA, Brett R, Alexander J, Pratt J, Roberts CW. Neuropsychiatric disease and Toxoplasma gondii infection. Neuroimmunomodulation. 2009; 16: 122-133.
5. Torrey EF, Yolken RH. Toxoplasma gondii and schizophrenia. Emerg Infect Dis. 2003; 9: 1375-1380.
6. Torrey EF, Bartko JJ, Lun ZR, Yolken RH. Antibodies to Toxoplasma gondii in patients with schizophrenia: A meta-Analysis. Schizophr Bull. 2007; 33: 729-736.
7. Torrey EF, Bartko JJ, Yolken RH. Toxoplasma gondii and other risk factors for schizophrenia: An update. Schizophr Bull. 2012; 38: 642-647.
8. Kozar Z. Badania nad toksoplazmoza wsród umyslowo chorych. Bull Inst Mar Trop Med Gdansk. 1953; 5: 146-173.
9. Carruthers VB, Suzuki Y. Effects of Toxoplasma gondii infection on the brain. Schizophr Bull. 2007; 33: 745-751.
10. Ebadi M, Akhlaghi H, Zamani MM, et al. The correlation between Toxoplasma gondii infection and schizophrenia: A comparative study with family members (control group). Scimetr. 2014; 2: e15386.
11. Dickerson F, Boronow J, Stallings C, Origoni A, Yolken R. Toxoplasma gondii in individuals with schizophrenia: Association with clinical and demographic factors and with mortality. Schizophr Bull. 2007; 33: 737-740.
12. Brown AS. Prenatal infection as a risk factor for schizophrenia. Schizophr Bull. 2006; 32: 200-202.
13. Brown AS, Patterson PH. Maternal infection and schizophrenia: Implications for prevention. Schizophr Bull. 2011; 37: 284-290.
14. Khandaker GM, Zimbron J, Lewis G, Jones PB. Prenatal maternal infection, neurodevelopment and adult schizophrenia: A systematic review of population-based studies. Psychol Med. 2013; 43: 239-257.
15. Brown AS, Schaefer CA, Quesenberry CP, Liu L, Babulas VP, Susser ES. Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring. Am J Psychiatry. 2005; 162: 767-773.
16. Mortensen PB, Norgaard-Pedersen B, Waltoft BL, et al. Toxoplasma gondii as a risk factor for early-onset schizophrenia: Analysis of filter paper blood samples obtained at birth. Biol Psychiatry. 2007; 61: 688-693.
17. Jones-Brando L, Torrey EF, Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res. 2003; 62: 237-244.
18. Webster JP, Lamberton PHL, Donnelly CA, Torrey EF. Parasites as causative agents of human affective disorders? The impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii's ability to alter host behaviour. Proc R Soc B. 2006; 273: 1023-1030.
19. Fond G, MacGregor A, Tamouza R, et al. Comparative analysis of anti-Toxoplasmic activity of antipsychotic drugs and valproate. Eur Arch Psychiatry Clin Neurosci. 2014; 264: 179-183.
20. Kar N, Misra B. Toxoplasma seropositivity and depression: A case report. BMC Psychiatry. 2004; 4: 1.
21. Webster JF, McConkey GA. Toxoplasma gondii-Altered host behaviour: Clues as to mechanisms of action. Folia Parasitol. 2010; 57: 95-104.
22. Gaur N, Gautam S, Gaur M, Sharma P, Dadheeh G, Mishra S. The biochemical womb of schizophrenia: A review. Indian J Clin Biochem. 2008; 23: 307-327.
23. Eyles D, Feldon J, Meyer U. Schizophrenia: Do all roads lead to dopamine or is this where they start? Evidence from two epidemiologically informed rodent models. Transl Psychiatry. 2012; 2: e81.
24. Campbell BM, Charych E, Lee AW, Moller T. Kynurenines in CNS disease: Regulation by inflammatory cytokines. Front Neurosci. 2014; 8: 12.
25. Minto A, Roberts FJ. The psychiatric complications of toxoplasmosis. Lancet. 1959; 1: 1180-1182.
26. Dube B, Benton T, Cruess DG, Evans DL. Neuropsychiatric manifestations of HIV infection and AIDS. J Psychiatry Neurosci. 2005; 30: 237-246.
27. Kamerkar S, Davis PH. Toxoplasma on the brain: Understanding host-pathogen interactions in chronic CNS infection. J Parasitol Res. 2012. DOI: 10.1155/2012/589295.
28. Vyas A, Sapolsky R. Manipulation of host behaviour by Toxoplasma gondii: What is the minimum a proposed proximate mechanism should explain? Folia Parasitol. 2010; 57: 88-94.
29. Hurley RA, Taber KH. Latent Toxoplasmosis gondii: Emerging evidence for influences on neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci. 2012; 24: 376-383.
30. Lyons RE, McLeod R, Roberts CW. Toxoplasma gondii tachyzoitebradyzoite interconversion. Trends Prasitol. 2002; 18: 198-201.
31. Venkatasubramanian G, Debnath M. Neuroimmunological aberrations and cerebral asymmetry abnormalities in schizophrenia: Select perspectives on pathogenesis. Clin Psychopharmacol Neurosci. 2014; 12: 8-18.
32. Muller N. The role of anti-inflammatory treatment in psychiatric disorders. Psychiatria Danubina. 2013; 25: 292-298.
33. Hanauer DA, Ramakrishnan N, Seyfried LS. Describing the relationship between cat bites and human depression using data from an electronic health record. PLoS ONE. 2013; 8: e70585.
34. Webster JP, Kaushik M, Bristow GC, McConkey GA. Toxoplasma gondii infection, from predation to schizophrenia: Can animal behaviour help us understand human behaviour J Exp Biol. 2013; 216: 99-112.
35. Fabiani S, Pinto B, Bruschi F. Toxoplasmosis and neuropsychiatric diseases: Can serological studies establish a clear relationship? Neurol Sci. 2013; 34: 417-425.
36. Montoya JG. Laboratory diagnosis of Toxoplasma gondii infection and toxoplasmosis. J Infect Dis. 2002; 185: S73-S82.
37. Meyer U. Developmental neuroinflammation and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 42: 20-34.
38. Henriquez SA, Brett R, Alexander J, Pratt J, Roberts CW. Neuropsychiatric disease and Toxoplasma gondii infection. Neuroimmunomodulation. 2009; 16: 122-133.
39. Schizophrenia Working Group of the Psychiatric Genomics Consortium: Biological insights from 108 schizophrenia-Associated genetic loci. Nature 2014; 511: 421-427.
40. Skaper SD, Facci L, Giusti P. Neuroinflammation, microglia and mast cells in the pathophysiology of neurocognitive disorders: A review. CNS Neurol Disord Drug Targets. 2014; 13: 1654-1666.